Rigel Pharmaceuticals, Inc.
RIGL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $511,017 | $334,986 | $320,366 | $296,823 |
| - Cash | $48,534 | $53,407 | $45,728 | $56,746 |
| + Debt | $60,880 | $61,044 | $61,066 | $59,965 |
| Enterprise Value | $523,363 | $342,623 | $335,704 | $300,042 |
| Revenue | $69,462 | $101,685 | $53,333 | $57,596 |
| % Growth | -31.7% | 90.7% | -7.4% | – |
| Gross Profit | $64,709 | $97,181 | $48,924 | $51,807 |
| % Margin | 93.2% | 95.6% | 91.7% | 89.9% |
| EBITDA | $30,117 | $62,463 | $13,968 | $17,781 |
| % Margin | 43.4% | 61.4% | 26.2% | 30.9% |
| Net Income | $27,900 | $59,613 | $11,446 | $14,341 |
| % Margin | 40.2% | 58.6% | 21.5% | 24.9% |
| EPS Diluted | 1.457 | 3.28 | 0.63 | 0.8 |
| % Growth | -55.6% | 420.6% | -21.3% | – |
| Operating Cash Flow | $24,031 | $30,537 | -$893 | $14,503 |
| Capital Expenditures | -$12 | $0 | $0 | -$26 |
| Free Cash Flow | $24,019 | $30,537 | -$893 | $14,477 |